# 2.2.2 Study BO42863 (ARROW)

**Page range:** 22â€“22

```text
2.2.2
Study BO42863 (ARROW)
ARROW is a non-randomized, open-label, Phase I/II study of pralsetinib in patients with
thyroid cancer, NSCLC and other advanced solid tumors. The study is ongoing, but
completed enrolment in December 2021 and last patient last visit was on 21 March
2024.
The clinical cut-off date of the study used for DSR authoring was the latest available
data-cut date of 04 March 20227.
```